A mist inhaler with the drug Spiriva has been shown to increase the risk of death by 52 percent in people with chronic obstructive pulmonary disease (COPD), according to a new review. The mist inhaler, called Respimat, which contains the drug Spiriva (tiotropium), is approved in 55 countries, but not yet in the United States. Spirivia is approved in the U.S. for COPD in a powdered form delivered with a “Handihaler,” which was not included in the review. The new study, led by Dr. Sonal Signh, an assistant professor of general internal medicine at the Johns Hopkins University School of Medicine in Baltimore, ... Read More
Righting Injustice is published by the Beasley Allen Law Firm. If you are interested in a free legal consultation, please take a few moments to fill out the contact form with as many details as possible. The more information you provide us, the better we can evaluate your claim.